Cargando…

P1082: SAFETY AND EFFICACY ANALYSIS IN OLDER PATIENTS TREATED WITHIN THE GATLA LH-05 PROTOCOL: PET-ADAPTED THERAPY AFTER 3 CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA

Detalles Bibliográficos
Autores principales:	Fiad, N. L., Prates, M. V., Fernandez, I., Kurgansky, N., Cerutti, A., Negri Aranguren, F., Guanchiale, L., Sackmann, F., Maradei, J., Enrico, A., Negri Aranguren, P., Pavlovsky, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430163/ http://dx.doi.org/10.1097/01.HS9.0000847196.45811.7e

Ejemplares similares

P1081: PET-ADAPTED THERAPY AFTER THREE CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA: LONG TERM FOLLOW UP OF THE GATLA LH-05 TRIAL
por: Pavlovsky, A., et al.
Publicado: (2022)

The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD
por: Binder, Adam F., et al.
Publicado: (2017)

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma
por: Vakkalanka, Bhanu, et al.
Publicado: (2011)

ABVD and BEACOPP regimens’ effects on fertility in young males with Hodgkin lymphoma
por: Amin, M. S. A., et al.
Publicado: (2020)

AllerGAtlas 1.0: a human allergy-related genes database
por: Liu, Jinying, et al.
Publicado: (2018)

Bladder Carcinoma after ABVD Chemotherapy for Hodgkin's Lymphoma: A Case Report
por: Gangopadhyay, Aparna, et al.
Publicado: (2012)

Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma
por: Bond, David A., et al.
Publicado: (2019)

Tissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphoma: a case report
por: Subbiah, Vivek, et al.
Publicado: (2007)

Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery
por: Schwenkglenks, Matthias, et al.
Publicado: (2010)

A case of blood triglyceride increased induced by ABVD therapy for classical Hodgkin lymphoma
por: Yonezawa, Ryo, et al.
Publicado: (2023)

Treatment of Hodgkin Lymphoma With ABVD Chemotherapy in Rural Rwanda: A Model for Cancer Care Delivery Implementation
por: DeBoer, Rebecca J., et al.
Publicado: (2020)

Maternal ABVD chemotherapy for Hodgkin lymphoma in a dichorionic diamniotic pregnancy: a case report
por: Cotteret, Camille, et al.
Publicado: (2020)

Outcomes in Patients with Classic Hodgkin Lymphoma Treated with ABVD: A Single-center Retrospective Study
por: Makiyama, Junya, et al.
Publicado: (2020)

The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy
por: Tamma, Roberto, et al.
Publicado: (2023)

A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity
por: Gibb, A, et al.
Publicado: (2013)

P023: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma
por: Mocikova, Heidi, et al.
Publicado: (2022)

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma
por: Porrata, L F, et al.
Publicado: (2013)

A case of Hodgkin’s lymphoma with severely impaired liver function treated successfully with gemcitabine followed by ABVD
por: Chakraborty, Rajshekhar, et al.
Publicado: (2015)

Body mass index-associated responses to an ABVD-like regimen in newly-diagnosed patients with Hodgkin lymphoma
por: Hu, Min, et al.
Publicado: (2023)

T065: Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
por: Entrop, Joshua P., et al.
Publicado: (2022)

PB2260: FIVE-YEAR SINGLE-CENTER EXPERIENCE IN THE TREATMENT OF ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA WITH ABVD
por: Vukovic, Vojin, et al.
Publicado: (2023)

Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence
por: Seshachalam, Arun, et al.
Publicado: (2019)

Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial
por: Ricardi, Umberto, et al.
Publicado: (2021)

Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling
por: Honoré, Bent, et al.
Publicado: (2022)

Effects of ABVD chemotherapy on ovarian function: epidemiology, hormonal dosages and ultrasound morphologic analyses in 270 patients with Hodgkin’s disease
por: Ciccarone, Mariavita, et al.
Publicado: (2023)

Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials
por: André, Marc P. E., et al.
Publicado: (2020)

Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?
por: Gunther, Jillian R., et al.
Publicado: (2020)

Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study
por: Suwanban, Tawatchai, et al.
Publicado: (2023)

Interleukin-2-330T/G and Interleukin-10-1082A/G Genetic Polymorphisms and B-Cell Non-Hodgkin Lymphoma
por: Joob, Beuy, et al.
Publicado: (2018)

IL-10 (−1082 G/A) polymorphism in Bataknese with schizophrenia
por: Mardhiyah, Sarah A., et al.
Publicado: (2023)

Sustained remission after ABVD treatment for interdigitating dendritic cell sarcoma
por: Helbig, Grzegorz, et al.
Publicado: (2014)

DoD2007: 1082 molecular biology databases
por: Babu, Padavala Ajay, et al.
Publicado: (2007)

PReS13-SPK-1082: Catastrophic antiphospholipid syndrome
por: Cervera, R
Publicado: (2013)

The Risk of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia in Hodgkin Lymphoma has Substantially Decreased in the ABVD Era Abolishing Mechlorethamine and Procarbazine and Limiting Volumes and Doses of Radiotherapy
por: Brusamolino, Ercole, et al.
Publicado: (2012)

P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL.
por: Dickinson, Michael, et al.
Publicado: (2023)

Whole-slide image analysis identifies a high content of Hodgkin Reed-Sternberg cells and a low content of T lymphocytes in tumor microenvironment as predictors of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD
por: Santisteban-Espejo, Antonio, et al.
Publicado: (2022)

Vivir es comprometerse
por: Aranguren Gonzalo, Luis A.
Publicado: (2001)

El doberman : adquisición, alimentación, cuidados, adiestramiento, reproducción
por: Aranguren, Miguel
Publicado: (1988)

Interleukin-10 -1082 G/A gene polymorphisms in Egyptian children with CAP: A case–control study
por: Azab, Seham F., et al.
Publicado: (2016)

Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting
por: Zheng, Serena, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_14psg1ipiae16sv1ammid9h7jf